13 results
10-K
2023 FY
NMRA
Neumora Therapeutics Inc.
7 Mar 24
Annual report
4:05pm
for the recycling and disposal of proteins and lipids in the lysosome. Numerous scientific studies have demonstrated that GCase mutations trigger lysosomal
S-8
EX-99.3
NMRA
Neumora Therapeutics Inc.
19 Sep 23
Registration of securities for employees
9:57pm
.
5.2 Share Recycling.
(a) If all or any part of an Award or Prior Plan Award expires, lapses or is terminated, converted into an award in respect
424B4
NMRA
Neumora Therapeutics Inc.
18 Sep 23
Prospectus supplement with pricing info
4:12pm
for the recycling and disposal of proteins and lipids in the lysosome. Numerous scientific studies have demonstrated that GCase mutations trigger lysosomal
S-1/A
NMRA
Neumora Therapeutics Inc.
11 Sep 23
IPO registration (amended)
6:07am
disorder. Mutations in the GBA gene are associated with PD (approximately 10% of PD patients). Functional GCase is crucial for the recycling
S-1
NMRA
Neumora Therapeutics Inc.
25 Aug 23
IPO registration
5:03pm
(approximately 10% of PD patients). Functional GCase is crucial for the recycling and disposal of proteins and lipids in the lysosome. Numerous
S-1
EX-10.7
j7jgcq47
25 Aug 23
IPO registration
5:03pm
DRS/A
bh9kbjs v1i5nn
9 Aug 23
Draft registration statement (amended)
12:00am
DRS/A
6qq lbulcholj
30 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
i51jk
2 Sep 22
Draft registration statement (amended)
12:00am
DRS/A
qc831cx0
10 Jun 22
Draft registration statement (amended)
12:00am
DRS/A
1jnp7qc7jo
2 May 22
Draft registration statement (amended)
12:00am
DRS/A
1csrs 6m95vw
23 Dec 21
Draft registration statement (amended)
12:00am
DRS
wyuio q17vxfmnkeuk
8 Nov 21
Draft registration statement
12:00am
- Prev
- 1
- Next